Cheryl Cohen
Directeur/Membre du Conseil chez CELLDEX THERAPEUTICS, INC.
Fortune : 1 M $ au 31/05/2024
Profil
Ms. Cheryl L.
Cohen is an Independent Director at Celldex Therapeutics, Inc. and a Lead Independent Director at ImmunityBio, Inc. She is on the Board of Directors at Celldex Therapeutics, Inc., ImmunityBio, Inc. and Aerpio Therapeutics, Inc. Ms. Cohen was previously employed as an Independent Director by Ignyte Acquisition Corp., an Independent Non-Executive Director by MEI Pharma, Inc., an Independent Director by NantKwest, Inc., an Independent Director by Aerpio Pharmaceuticals, Inc., an Independent Director by Vital Therapies, Inc., an Independent Director by CytRx Corp., an Independent Director by Tokai Pharmaceuticals, Inc., an Independent Director by Novus Therapeutics, Inc., a Chief Commercial Officer by Orion Acquisition Corp.
II, a President by CLC Consulting LLC, a Vice President-Strategic Commercial Group by Health Care Systems, Inc., a Vice President-Rheumatology Franchise by Centocor, Inc., a Vice President-Rheumatology Franchise by Centocor Ortho Biotech, Inc., a Principal by Solvay Pharmaceuticals, Inc., and a Vice President-Rheumatology Franchise by Johnson & Johnson.
She also served on the board at Protein Sciences Corp.
She received her undergraduate degree from Saint Joseph College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IMMUNITYBIO INC
0,03% | 11/06/2024 | 200 617 ( 0,03% ) | 1 M $ | 31/05/2024 |
| 05/04/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Postes actifs de Cheryl Cohen
| Sociétés | Poste | Début |
|---|---|---|
| IMMUNITYBIO, INC. | Directeur/Membre du Conseil | 01/06/2019 |
| CELLDEX THERAPEUTICS, INC. | Directeur/Membre du Conseil | 16/06/2022 |
Aerpio Therapeutics, Inc.
 Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Directeur/Membre du Conseil | 01/06/2018 |
Anciens postes connus de Cheryl Cohen
| Sociétés | Poste | Fin |
|---|---|---|
| MEI PHARMA, INC. | Directeur/Membre du Conseil | 06/12/2022 |
| AERPIO PHARMACEUTICALS | Directeur/Membre du Conseil | 26/08/2021 |
| ELEDON PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 30/06/2020 |
Tokai Pharmaceuticals, Inc.
 Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | Directeur/Membre du Conseil | 01/06/2020 |
Vital Therapies, Inc.
 Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | Directeur/Membre du Conseil | 12/04/2019 |
Formation de Cheryl Cohen
| Saint Joseph College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 6 |
|---|---|
| LADRX CORPORATION | Health Technology |
| ELEDON PHARMACEUTICALS, INC. | Health Technology |
| MEI PHARMA, INC. | Health Technology |
| IMMUNITYBIO, INC. | Health Technology |
| CELLDEX THERAPEUTICS, INC. | Health Services |
| JOHNSON & JOHNSON | Health Technology |
| Entreprise privées | 13 |
|---|---|
Medivation LLC (California)
 Medivation LLC (California) Pharmaceuticals: MajorHealth Technology Medivation LLC engages in the development and commercialization of novel therapies to treat serious diseases for which there are limited treatment options. The company was founded by Clarence Patrick Machado and David T. Hung in 2004 and is headquartered in San Francisco, CA. | Health Technology |
| CLC Consulting LLC | |
Centocor, Inc.
 Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | Health Technology |
Solvay Pharmaceuticals, Inc.
 Solvay Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Solvay Pharmaceuticals, Inc manufactures pharmaceutical products. The company produces therapies for cardi-metabolic, gastroenterological, and neurological disorders. Its brands include Androgel, Klonopin, and ACEON drugs. Solvay Pharmaceuticals was founded by Ernest Solvay in 1863 and is located in Marietta, GA. | Health Technology |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | Health Technology |
Protein Sciences Corp.
 Protein Sciences Corp. BiotechnologyHealth Technology Protein Sciences Corp. engages in developing and manufacturing recombinant human and veterinary vaccines, therapeutics and diagnostics. The firm develops vaccines for influenza, SARS and other diseases. The company was founded by Mark A. Cochran and Franklin Volvovitz in 1983 and is headquartered in Meriden, CT. | Health Technology |
Vital Therapies, Inc.
Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | Health Technology |
Health Care Systems, Inc.
 Health Care Systems, Inc. Packaged SoftwareTechnology Services Health Care Systems, Inc. provides robust physician order entry and medication management solutions. The private company is based in Montgomery, AL. The CEO of the company is Erwin Cablayan. | Technology Services |
Aerpio Pharmaceuticals, Inc.
 Aerpio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The firm's product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 16, 2007 and is headquartered in Cincinnati, OH. | Health Technology |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Health Technology |
NantKwest, Inc.
 NantKwest, Inc. BiotechnologyHealth Technology NantKwest, Inc. engages in the research and development of immunotherapies. It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. The company was founded by Gary N. Keller and Hans Georg Klingemannon October 7, 2002 and is headquartered in San Diego, CA. | Health Technology |
Ignyte Acquisition Corp.
 Ignyte Acquisition Corp. Financial ConglomeratesFinance Ignyte Acquisition Corp. is a blank check company, which was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities. The company was founded on August 6, 2020 and is headquartered in New York, NY. | Finance |
Janssen Biotech, Inc.
 Janssen Biotech, Inc. Pharmaceuticals: MajorHealth Technology Janssen Biotech, Inc. engages in the development and marketing of prescription drugs. The company is headquartered in Horsham, PA. | Health Technology |
